Pen Needles was Embecta’s largest product and service line in fiscal 2025, bringing in $784.10M of $1.08B (73%).
| Product and Service | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Pen Needles | $824.60M | $829.20M | $844.40M | $784.10M |
| Syringes | $156.00M | $138.10M | $126.20M | $124.60M |
| Safety | $119.60M | $126.30M | $129.40M | $137.80M |
| Contract Manufacturing | $15.00M | $13.00M | $12.80M | $19.90M |
| Other | $14.30M | $14.20M | $10.30M | $14.00M |
| Total | $1.13B | $1.12B | $1.12B | $1.08B |
Embecta brought in $1.08B from its five product and service lines in fiscal 2025, the year ended September 30, 2025. That was down 3.8% from $1.12B in fiscal 2024. Pen Needles was the largest at $784.10M (72.6%), ahead of Safety at $137.80M (12.8%) and Syringes at $124.60M (11.5%). The other two lines brought in $33.90M combined.
Compared with fiscal 2024, Safety grew fastest, up 6.5% to $137.80M, while Pen Needles fell the most, down 7.1% to $784.10M. From fiscal 2022 to 2025, combined revenue from these lines fell from $1.13B to $1.08B, a compound annual decline of 1.5%. Pen Needles' share held steady at about 72.6%.
United States was Embecta’s largest region in fiscal 2025, bringing in $579.10M of $1.08B (54%).
| Geography | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|
| United States | $600.30M | $601.40M | $607.20M | $579.10M | ||
| International | $529.20M | $519.40M | $515.90M | $501.30M | ||
| Total | $1.13B | $1.12B | $1.12B | $1.08B |
Embecta brought in $1.08B from its two regions in fiscal 2025, the year ended September 30, 2025. That was down 3.8% from $1.12B in fiscal 2024. United States was the largest at $579.10M (53.6%), ahead of International at $501.30M (46.4%).
Compared with fiscal 2024, International fell 2.8% to $501.30M and United States fell 4.6% to $579.10M. From fiscal 2022 to 2025, combined revenue from these regions fell from $1.13B to $1.08B, a compound annual decline of 1.5%. United States' share held steady at about 53.6%.
Embecta (EMBC) reports its revenue by product and service and by geography. In fiscal 2025, Pen Needles was its largest product and service line, bringing in $784.10M (72.6% of the total), followed by Safety at $137.80M (12.8%).
Pen Needles was Embecta's largest product and service line in fiscal 2025, bringing in $784.10M, or 72.6% of the $1.08B total across its five product and service lines.
United States was Embecta's largest region in fiscal 2025, bringing in $579.10M, or 53.6% of the $1.08B total across its two regions.
Among Embecta's product and service lines that make up at least 2% of revenue, Safety grew fastest in fiscal 2025, up 6.5% from $129.40M to $137.80M.
Every figure comes from Embecta's annual financial filings, as reported. Each line keeps the name Embecta gives it, and years follow its fiscal calendar.
Embecta's revenue by product and service goes back to fiscal 2022, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.